Therapeutic misconception—a false belief that individuals will benefit from participating in research—can bias informed consent. Ethics consultants can help by engaging participants’ and researchers’ understandings of risks and benefits and by asking good questions about the influences of researchers’ enthusiasm.
AMA J Ethics. 2018;20(11):E1100-1106. doi:
10.1001/amajethics.2018.1100.
Professional society guidelines can be used to set standards for clinical practice instead of government. This approach could help if federal or state policymakers view discarding embryos as ethically equivalent to abortion.
AMA J Ethics. 2018;20(12):E1160-1167. doi:
10.1001/amajethics.2018.1160.
The DSM-5 Task Force’s handling of the ethical controversy over the bereavement exclusion demonstrates the need for more inclusive deliberative processes.
AMA J Ethics. 2017;19(2):192-198. doi:
10.1001/journalofethics.2017.19.2.pfor2-1702.
Despite a tendency to react otherwise, there is no obvious reason to believe that economically disadvantaged people ought not to be exposed to the same levels of research risk as the rest of the population.
The question that comes to mind when one considers the risks of a clinical trial is, “Why would anyone agree to participate?” Interviews with trial volunteers and their family members make clear that often it is the appeal of discovering something new and unknown.